Opiant Pharmaceuticals, Inc. Sustainability Profile
Opiant Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, is dedicated to developing innovative treatments for addiction and related disorders. Founded in 2014, Opiant has made significant strides in the industry, particularly with its flagship product, Narcan® (naloxone), which is pivotal in reversing opioid overdoses. With a focus on addressing the urgent needs of patients and healthcare providers, Opiant's unique approach combines advanced science with a commitment to public health. The company operates primarily in the US but is also expanding its reach into international markets. Recognised for its contributions to combating the opioid crisis, Opiant continues to solidify its position as a key player in the biopharmaceutical sector, striving to improve lives through effective and accessible treatment solutions.
DitchCarbon Score
How does Opiant Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Opiant Pharmaceuticals, Inc.'s score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Opiant Pharmaceuticals, Inc.'s reported carbon emissions
Opiant Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any specific reduction targets or initiatives related to climate commitments. Without emissions data or defined climate strategies, Opiant Pharmaceuticals appears to be in the early stages of addressing its environmental impact. As the pharmaceutical industry increasingly focuses on sustainability, Opiant may need to consider developing measurable climate goals and reporting frameworks to align with industry standards and expectations.
How Carbon Intensive is Opiant Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Opiant Pharmaceuticals, Inc.'s Location?
Opiant Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Opiant Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
